What is the 13F Pro Quality Score for NEOG?

13F Pro ranks NEOGEN CORP (NEOG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NEOG's current score at https://13fpro.ai/research/NEOG (free sign-up required for the full ranking).

Where does 13F Pro source NEOG data?

All NEOGEN CORP fundamentals and ownership data come directly from SEC EDGAR. NEOGEN CORP files with the SEC under CIK 711377. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NEOG in?

NEOGEN CORP (NEOG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NEOG research updated on 13F Pro?

NEOG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEOGEN CORP(NEOG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 711377 NEOG stock profile & AI dashboard →

13F Pro Quality Score

36.9/100

Rank #2,080 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

23.6/100

Profitability

35.3/100

Balance Sheet

34.8/100

Earnings Quality

30.0/100

Free Cash Flow

31.5/100

Institutional Flow

91.6/100

Revenue Scale

46.8/100

Dilution Risk

41.9/100

NEOG Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NEOGEN CORP (NEOG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NEOG at 36.9/100 on a 32-signal composite quality model, placing it at rank #2,080 of 2,879 stocks — the bottom half of the AI-ranked universe. NEOG scores in the top quartile across institutional flow (91.6). Areas of concern include revenue growth (23.6) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 41.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), NEOGEN CORP reports quarterly revenue of $211.2M, net income of $-17.0M, free cash flow of $11.1M. Top institutional holders of NEOG by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEOG trades on the Nasdaq exchange and files with the SEC under CIK 711377. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEOG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEOGEN CORP directly from SEC EDGAR. NEOGEN CORP's 13F Pro composite quality score has ranged between 8 and 62 since 2021, currently 36.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about NEOGEN CORP

Quirks, history, and lore behind NEOG — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life-sciences company · listed on Nasdaq · headquartered in Michigan · serves customers in food and animal safety industries.
2
The Numbers
Annual revenue in the range of $900 million to $1 billion after a major acquisition roughly doubled its size — still a small-cap by Wall Street standards.
3
The History
Founded in 1971, it spent decades quietly building a niche in diagnostic test kits before going public and expanding globally through acquisitions.
4
The Secret
Its two main divisions essentially ask: is this food safe to eat? and is this animal healthy? — making it indispensable to farms, labs, and food processors worldwide.
5
The Lore
It completed a landmark merger with 3M's food safety division in 2022, a deal that transformed it from a niche player into a global leader in pathogen and allergen detection.
6
The Giveaway
If your burger doesn't have E. coli and your livestock aren't secretly sick, there's a good chance this Lansing, Michigan company ran the test — ticker starts with NEO.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$211.2M

Net Income

Q3 2026

$-17.0M

Free Cash Flow

Q3 2026

$11.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.2% YoY

$894.7MFY 2025

FY21 $468.5MFY23 $822.4MFY24 $924.2MFY25 $894.7M

Net Income

-11491.6% YoY

$-1.09BFY 2025

FY21 $60.9MFY23 $-22.9MFY24 $-9.4MFY25 $-1.09B

Operating Income

-1908.6% YoY

$-1.06BFY 2025

FY21 $74.2MFY23 $37.5MFY24 $58.7MFY25 $-1.06B

EPS (Diluted)

-12475.0% YoY

$-5.03FY 2025

FY21 $0.28FY23 $-0.12FY24 $-0.04FY25 $-5.03

Total Assets

-24.3% YoY

$3.44BFY 2025

FY21 $920.2MFY23 $4.55BFY24 $4.55BFY25 $3.44B

Total Debt

+0.3% YoY

$1.80BFY 2025

FY21 —FY23 $1.79BFY24 $1.79BFY25 $1.80B

Op. Cash Flow

+65.2% YoY

$58.2MFY 2025

FY21 $81.1MFY23 $41.0MFY24 $35.3MFY25 $58.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$894.7M -3.2%	$924.2M +12.4%	$822.4M +75.6%	$468.5M +12.0%	$418.2M +5.1%	$397.9M
Net Income	$-1.09B -11491.6%	$-9.4M +58.8%	$-22.9M -137.6%	$60.9M +2.4%	$59.5M -5.8%	$63.1M
Operating Income	$-1.06B -1908.6%	$58.7M +56.4%	$37.5M -49.4%	$74.2M +9.8%	$67.5M -3.8%	$70.2M
EPS (Diluted)	$-5.03 -12475.0%	$-0.04 +66.7%	$-0.12 -142.1%	$0.28 +1.8%	$0.28 -7.4%	$0.30
Total Assets	$3.44B -24.3%	$4.55B -0.1%	$4.55B +394.9%	$920.2M +15.4%	$797.2M +29.0%	$618.0M
Total Debt	$1.80B +0.3%	$1.79B +0.3%	$1.79B	—	—	—
Operating Cash Flow	$58.2M +65.2%	$35.3M -14.0%	$41.0M -49.4%	$81.1M -5.6%	$85.9M +24.2%	$69.1M

AI Insight: NEOG Financial Trends

Neogen shows persistent revenue volatility and operational struggles with massive $612M net loss in Q2 2025 driving equity down 34% from peak.

• Revenue declined from $225M in Q4 2025 to $211M in Q1 2026, continuing erratic quarterly pattern.

• Equity fell sharply from $3,144M in Q2 2024 to $2,102M in Q1 2026, a 33% decline.

• Operating income turned negative in five of last six quarters through Q1 2026.

⚠ Debt spiked from $891M in Q1 2025 to $1,797M in Q2 2025, coinciding with massive loss.

⚠ Operating cash flow stabilized around $11M-$23M range in recent four quarters despite operational losses.

AI Insight: NEOG Ratio Trends

NEOGEN shows severe operational distress with operating margins collapsing from 5.5% in Q2 2024 to -73.0% TTM, while debt-to-equity jumped to 0.77.

• Operating margin deteriorated dramatically from 5.5% in Q2 2024 to -1.5% in Q1 2026, with TTM at -73.0%.

• ROIC turned deeply negative at -17.1% TTM versus marginally positive 1.1% in Q2 2024.

• Debt-to-equity ratio increased from 0.57 in early 2024 to 0.77 currently, indicating rising leverage.

⚠ Massive Q2 2025 spike in negative returns (ROE -118.2%, ROA -71.1%) suggests potential one-time charges or impairments.

⚠ Sequential quarterly improvement in operating margins from -7.7% in Q3 2025 to -1.5% in Q1 2026.

Get alerted when NEOG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEOGEN CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NEOG

BlackRock, Inc.
$303.0M32,621,005 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$119.2M12,832,264 sh
VANGUARD CAPITAL MANAGEMENT LLC
$88.9M9,565,046 sh
DIMENSIONAL FUND ADVISORS LP
$84.8M9,132,021 sh
ING GROEP NV
$82.7M8,904,300 sh
STATE STREET CORP
$79.8M8,590,344 sh
MACKENZIE FINANCIAL CORP
$72.5M7,803,226 sh
Neuberger Berman Group LLC
$72.0M7,751,718 sh
Hudson Bay Capital Management LP
$60.4M6,500,180 sh
Gates Capital Management, Inc.
$58.1M6,258,649 sh

Fund	Value	Shares
BlackRock, Inc.	$303.0M	32,621,005
VANGUARD PORTFOLIO MANAGEMENT LLC	$119.2M	12,832,264
VANGUARD CAPITAL MANAGEMENT LLC	$88.9M	9,565,046
DIMENSIONAL FUND ADVISORS LP	$84.8M	9,132,021
ING GROEP NV	$82.7M	8,904,300
STATE STREET CORP	$79.8M	8,590,344
MACKENZIE FINANCIAL CORP	$72.5M	7,803,226
Neuberger Berman Group LLC	$72.0M	7,751,718
Hudson Bay Capital Management LP	$60.4M	6,500,180
Gates Capital Management, Inc.	$58.1M	6,258,649

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NEOG on your watchlist

Track score changes the day NEOGEN CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NEOG a good stock to buy?

13F Pro's AI-powered analysis of NEOGEN CORP (NEOG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEOG are available on the NEOG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NEOG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEOG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEOGEN CORP's investment landscape.